Bit Bio raises series A funding for its programming approach to human cells.
23.06.2020Bit Bio raises series A funding for its programming approach to human cells.
Bit Bio raises series A funding for its programming approach to human cells.
23.06.2020Bit Bio raises series A funding for its programming approach to human cells.
Discovery Drive-based synthetic biology Bit Bio has closed a $41.5million Series A investment.
16.06.2020²»Á¼Ñо¿Ëù closes series A $41.5 million funding.
13.06.2020Bit Bio announces agreement with Abcam, to make Bit Bio’s iPSC derived functional human cells widely available.
26.02.2020²»Á¼Ñо¿Ëù and Charles River announce strategic partnership.
11.12.2019Paul Morril, Horizon Discovery co-founder joins as CBO and Florian Schuster, Tessa Therapeutics, as CFO.
29.10.2019Elpis Biomed rebrands to ²»Á¼Ñо¿Ëù.
14.10.2019²»Á¼Ñо¿Ëù combines the concepts of coding and biology to provide human cells for research, drug discovery and cell therapy.
14.10.2019Reprogramming human cells by ²»Á¼Ñо¿Ëù.
07.10.2019